Hongru Li | Brain Metastasis | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Hongru Li | Brain Metastasis | Best Researcher Award

Fuzhou University Affiliated Provincial Hospital | China

Dr. Hongru Li, MD/PhD, is a distinguished clinician-scientist and Chief Physician in the Department of Respiratory and Critical Care Medicine at Fujian Provincial Hospital, Fujian Medical University. With a career dedicated to advancing respiratory medicine and oncology, his expertise lies in lung cancer, metastasis mechanisms, and innovative therapeutic strategies. Over the years, he has combined clinical excellence with groundbreaking research, focusing on molecular pathways and targeted therapies. Dr. Li has published extensively in reputable journals, contributing to understanding brain and bone metastasis in non-small cell lung cancer. His leadership extends to supervising clinical innovation projects funded by national and provincial research grants. Recognized as an outstanding respiratory scholar, he has made notable contributions in translational medicine, bridging laboratory findings with patient care. His research on nanoliposomes, ceramide pathways, and genetic susceptibility in lung cancer exemplifies his commitment to improving treatment outcomes and patient survival in respiratory oncology.

Profile

ORCID

Education

Dr. Hongru Li’s academic foundation is firmly rooted in medicine and specialized respiratory science. He earned his Doctor of Medicine degree at Fujian Medical University, where he developed his core clinical knowledge and interest in pulmonary health. To deepen his expertise, he pursued postgraduate studies in respiratory medicine at Fujian Medical University, gaining hands-on exposure to advanced diagnostic and therapeutic approaches in pulmonary and critical care. His academic journey culminated with a PhD in Respiratory Medicine from Southern Medical University in Guangzhou, where he focused on molecular mechanisms of lung cancer progression and metastasis. His doctoral research provided a solid grounding in translational medicine, integrating clinical insights with cellular and molecular biology. This comprehensive educational background has enabled him to pursue a career balancing patient care with high-impact research, positioning him as a leader in respiratory medicine, oncology, and translational research with a strong focus on innovation and clinical application.

Experience

Dr. Hongru Li has accumulated extensive clinical and academic experience at Fujian Provincial Hospital, where he has advanced through progressive leadership roles in respiratory and critical care medicine. Starting as a resident doctor, he gained experience in managing complex respiratory cases, developing proficiency in critical care interventions. He then served as an attending doctor, where he refined his clinical judgment and mentored junior staff. His expertise led to his appointment as Associate Chief Physician, where he oversaw specialized clinical programs and research initiatives. Currently, as Chief Physician, Dr. Li leads the Department of Respiratory and Critical Care Medicine, managing advanced patient care, research collaborations, and clinical training. His responsibilities span from clinical decision-making to developing research projects funded by provincial and national agencies. With deep involvement in translational research, he bridges laboratory discoveries with real-world patient care, positioning him as both a skilled clinician and an innovative medical researcher.

Awards and Honors

Dr. Hongru Li has been recognized for his exceptional contributions to clinical medicine, research innovation, and academic excellence. Early in his career, he received the Excellent Graduate Award and Excellent Postgraduate Award from Fujian Medical University, reflecting his academic dedication and professional promise. His trajectory of excellence was further reinforced with the prestigious Outstanding Youth Respiratory Scholar Award for Clinical Innovation in China, acknowledging his groundbreaking research and leadership in respiratory medicine. These honors underscore his commitment to advancing lung cancer research, patient care, and translational medicine. His ability to secure competitive research funding and lead innovative studies further reflects his recognition as a trusted expert in his field. In addition, his patents and numerous peer-reviewed publications highlight the impact of his scientific contributions. These accolades collectively demonstrate not only his academic excellence but also his role as a leading physician-researcher shaping the future of respiratory and oncology medicine.

Research Focus

Dr. Hongru Li’s research centers on the molecular mechanisms driving lung cancer progression and metastasis, with particular emphasis on brain and bone metastases in non-small cell lung cancer. He explores signaling pathways, genetic susceptibility, and the role of lipids and ceramide metabolism in tumor development. His studies have investigated proteins such as livin, RPTOR, and ceramide synthase in regulating tumor proliferation, apoptosis, and metastatic spread. Through innovative approaches, including nanoliposome-based therapies, he seeks to inhibit cancer metastasis and improve treatment responses. He has also examined genetic polymorphisms and signaling cascades, such as the PI3K/AKT/mTOR and Wnt pathways, to understand cancer susceptibility and therapy resistance. His translational research aims to transform laboratory findings into clinical applications, offering new diagnostic biomarkers and therapeutic targets. Supported by national and provincial grants, his work significantly contributes to advancing precision medicine, improving survival, and developing novel treatment strategies for patients with lung cancer.

 

Publications

 

Title: KLF9 Inhibits Brain Metastasis of Non‐Small Cell Lung Cancer by Regulating Ceramide Synthase 1 Synthesis
Year: 2025

Title: Efficacy of Prophylactic Cranial Irradiation in Early to Mid-stage Small Cell Lung Cancer Patients in the Era of Magnetic Resonance Imaging
Year: 2024

Title: Development and validation of a nomogram model based on blood-based genomic mutation signature for predicting the risk of brain metastases in non-small cell lung cancer
Year: 2024

Title: Antibacterial effect of phage cocktails and phage-antibiotic synergy against pathogenic Klebsiella pneumoniae
Year: 2024

Title: Clinical application value of metagenome next-generation sequencing in pulmonary diffuse exudative lesions: a retrospective study
Year: 2024

Title: Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib
Year: 2024

Title: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding
Year: 2024

Conclusion

Dr. Hongru Li exemplifies the integration of clinical expertise and research innovation, dedicated to advancing respiratory and cancer medicine through groundbreaking studies, translational discoveries, and compassionate patient care.

Anett Hudák | Neurodegeneration | Women Researcher Award

Published on by Cognitive Scientist Awards

Ms. Anett Hudák | Neurodegeneration | Women Researcher Award

Anett Hudák is a skilled molecular biologist with deep expertise in neurobiology, virology, and molecular pathology. She earned her MSc in Molecular Biology from the University of Debrecen with a specialization in biomedical sciences and pharmacology. Over the years, she has significantly contributed to the understanding of cellular communication, amyloid pathology, and viral entry mechanisms through her work on syndecans. With professional experience spanning academia and industry, Anett currently serves as a molecular biologist at Pharmacoidea Ltd., where she leads impactful research on Alzheimer’s disease, SARS-CoV-2, and neurodegeneration. Her publications in high-impact journals like Scientific Reports and International Journal of Molecular Sciences reflect her strong research acumen. Anett’s extensive training in laboratory techniques, radiation protection, and animal experimentation, along with her dedication and collaborative mindset, make her a valued asset in translational biomedical research. She continues to drive discovery at the intersection of molecular biology and therapeutic innovation.

Profile

🎓 Education

Anett Hudák began her academic journey at Benka Gyula Lutheran Primary School and graduated from Andrássy Gyula Secondary School. She completed her BSc in Biology with a specialization in Laboratory Operations at the University of Debrecen’s Faculty of Science and Technology. She further pursued an MSc in Molecular Biology at the University of Debrecen’s Faculty of Medicine, specializing in Biomedical Sciences and Pharmacology. During her studies, she also received extended-level radiation protection training from the University of Debrecen’s Radiation Protection Service. Anett later earned a Certification in Laboratory Animal Science from the Institutional Animal Welfare Committee at Semmelweis University. Her academic formation has been enriched by intensive hands-on research training in various biomedical techniques including PCR, genotyping, electrophoresis, immunohistochemistry, and animal experimentation. This solid educational background has laid the groundwork for her successful transition into a career in academic and industrial molecular biology research.

🧪 Experience

Anett Hudák has a rich portfolio of research and laboratory experience, beginning with her early work on HPV detection in cervical cancer diagnostics at the Institute of Medical Microbiology, University of Debrecen. She expanded her expertise during her research internship at the Department of Anatomy, Histology and Embryology, where she investigated IL-1RI’s role in inflammatory pain models. From 2012 to 2014, she gained proficiency in cell biology techniques including immunofluorescence and Western blotting. She worked as a laboratory biologist at the Institute of Physiology, Semmelweis University (2015–2016), contributing to studies on lymphangiogenesis in embryonic development. Since 2016, she has been a molecular biologist at Pharmacoidea Ltd., conducting translational research on syndecans in viral transmission, amyloid aggregation, and neurodegenerative diseases. Her contributions to scientific conferences and collaborative publications demonstrate her ability to lead and participate in high-impact research projects that bridge molecular science and therapeutic development.

🏅 Awards and Honors

While formal awards are not extensively listed in Anett Hudák’s CV, her achievements are evident through her selection for prominent speaking roles and poster presentations at respected conferences such as the Pannonia Congress of Pathology (2014), MÉT 2015, and FAMÉ 2016. Her research has consistently been showcased in these forums, highlighting its relevance and impact. Furthermore, Anett’s work has resulted in numerous peer-reviewed publications in top-tier journals like Scientific Reports and International Journal of Molecular Sciences, indicating recognition by the scientific community. Her collaborative publications with international experts, such as Martin Hofmann-Apitius and Mimoun Azzouz, underscore her respected standing in biomedical research. Anett’s ability to lead first-author publications and contribute significantly to multi-author research reflects a level of distinction that is often synonymous with academic honors. Her rising trajectory in neurodegenerative and virology research suggests she is well-positioned for future scientific accolades and leadership roles.

🔬 Research Focus

Anett Hudák’s research centers on the role of syndecans in cellular communication, neurodegenerative disease pathology, and viral entry mechanisms. Her work has significantly contributed to understanding how these membrane proteins facilitate the internalization and aggregation of amyloid-β, α-synuclein, and tau—key proteins involved in Alzheimer’s and Parkinson’s diseases. She also explores how syndecans enable SARS-CoV-2 entry, including variants like Delta and Omicron, offering insights into COVID-19 pathogenesis and therapeutic intervention. Recent studies delve into the interaction between apolipoproteins and syndecans and how these pathways impact cellular events relevant to amyloid disorders. Her use of tissue decolorization, single-cell resolution imaging, and endocytosis analysis has positioned her research at the forefront of molecular neuroscience and virology. Anett’s interdisciplinary approach, spanning molecular biology, cell signaling, and pathology, not only addresses fundamental mechanisms but also aims to inform novel therapeutic strategies for infectious and neurodegenerative diseases.

✅ Conclusion

Anett Hudák is a dedicated and impactful molecular biologist whose research on syndecans, neurodegeneration, and viral entry has advanced both basic science and translational applications in biomedicine.

Publications

Jesus Avila | Tauopathies | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Jesus Avila | Tauopathies | Best Researcher Award

Dr. Jesus Avila is a distinguished cognitive scientist and Professor ad honorem at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), Spain. He obtained his degree in Chemistry and PhD in Molecular Biology from Universidad Complutense Madrid, focusing on RNA polymerase in B. subtilis. His postdoctoral research at NIH, USA, centered on the SV40 virus. Throughout his prolific career, Dr. Avila has made groundbreaking contributions to understanding the neuronal cytoskeleton, particularly tau protein, its role in Alzheimer’s disease, and tauopathies. With over 694 published journal articles, 33 books, 4 patents, and collaborations across the USA, France, UK, Germany, and Spain, his work is internationally recognized. He serves on editorial boards of prestigious journals including EMBO J, FEBS Letters, Neuroscience, and Journal of Alzheimer’s Disease (Deputy Editor). Dr. Avila is a member of EMBO, Academia Europaea, AAAS, and Royal Academies of Sciences and Medicine of Spain.

Professional Profile

Education

Dr. Jesus Avila pursued his higher education at Universidad Complutense Madrid (UCM), earning a degree in Chemistry. He further specialized by completing a PhD in Molecular Biology at UCM, where his research focused on the B. subtilis RNA polymerase system. This solid foundation in molecular biology provided him with the expertise to investigate complex neurobiological mechanisms. He then advanced his academic career with postdoctoral training at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, where he studied the SV40 virus—a crucial step that introduced him to advanced molecular virology and neurobiology techniques. This diverse academic background enabled him to establish a globally recognized research portfolio in neurodegeneration, particularly tau protein’s role in neuronal function and dysfunction.

Experience

Dr. Avila has an illustrious career spanning several decades at the Centro de Biologia Molecular Severo Ochoa (CBM-CSIC), where he has led pioneering research into the neuronal cytoskeleton, tau protein dysfunction, and neurodegenerative diseases. His early research at NIH on SV40 virus provided him with robust molecular expertise, which he translated into comprehensive studies on tauopathies and Alzheimer’s disease upon returning to Spain. Dr. Avila has successfully led over 30 major research projects, consulted on 8 industry collaborations, and published 694 peer-reviewed articles. His work includes the authorship of 33 books and the filing of 4 patents. Through sustained collaborations with global leaders in neuroscience from the USA, France, UK, Germany, and Spain, he has significantly advanced the understanding of aging and cognitive decline. His academic leadership and editorial roles underscore his vast experience in guiding both research and scientific discourse.

Research Interests

Dr. Avila’s research primarily investigates the neuronal cytoskeleton, with a central focus on tau protein and its role in neurodegeneration. Beginning with tau’s structural function in neurons, his work has expanded to explore how tau dysfunction contributes to Alzheimer’s disease and other tauopathies. Utilizing molecular and cellular approaches, including advanced mouse models, he has dissected the pathological mechanisms linking tau pathology to cognitive decline. Recognizing aging as the principal risk factor for Alzheimer’s disease, his current investigations target neuronal rejuvenation strategies to mitigate age-associated neurodegeneration. His integrative approach combines molecular biology, neurogenetics, and translational models, contributing significantly to the understanding of disease progression and potential therapeutic interventions. Through over 694 publications, 33 books, multiple patents, and international collaborations, Dr. Avila has substantially advanced the field of cognitive neuroscience, particularly in understanding and combating tau-mediated cognitive disorders.

Awards

Dr. Avila’s exemplary contributions have earned him numerous prestigious honors. He is an elected member of EMBO (European Molecular Biology Organization), Academia Europaea, AAAS (American Association for the Advancement of Science), and both the Royal Academies of Sciences and Medicine of Spain—testament to his global recognition and scientific excellence. His editorial appointments with highly respected journals such as EMBO J, FEBS Letters, Neuroscience, and his role as Deputy Editor of the Journal of Alzheimer’s Disease further validate his authority in cognitive and neurodegenerative research. His citation index surpasses 100 on Scopus, reflecting the significant influence of his work. His extensive collaborations with leading international research teams highlight his status as a respected leader in the global scientific community. The combination of his research excellence, mentorship, and leadership has positioned him as one of the foremost experts in cognitive science and neurobiology.

Conclusion

Dr. Jesus Avila’s distinguished career combines pioneering research on tau protein and Alzheimer’s disease, extensive international collaborations, over 694 publications, leadership roles in major journals, multiple prestigious memberships, and an unwavering focus on neuronal rejuvenation strategies, positioning him as a world-leading cognitive scientist whose work continues to advance global understanding of neurodegeneration.

 Publications

  • Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer’s disease

    Experimental Neurology
    2025 | Journal article
    DOI: 10.1016/j.expneurol.2024.115049

    EID:

    2-s2.0-85208758184

    Part ofISSN: 10902430 00144886
    CONTRIBUTORS: Merino-Serrais, P.; Soria, J.M.; Arrabal, C.A.; Ortigado-López, A.; Esparza, M.Á.G.; Muñoz, A.; Hernández, F.; Ávila, J.; DeFelipe, J.; León-Espinosa, G.

  • Retrotransposon Protein L1 ORF1p Expression in Aging Central Nervous System

    International Journal of Molecular Sciences
    2025-05-04 | Journal article
    DOI: 10.3390/ijms26094368
    CONTRIBUTORS: Laura Vallés-Saiz; Aaron Abdelkader-Guillén; Jesús Ávila; Félix Hernández

  • Shapeshifter W-Tau Peptide Inhibits Tau Aggregation and Disintegrates Paired Helical Filaments

    Biochemistry
    2025-04-15 | Journal article
    DOI: 10.1021/acs.biochem.4c00809
    CONTRIBUTORS: Indalo Domene-Serrano; Raquel Cuadros; Vega García-Escudero; Francisco Vallejo-Bedia; Ismael Santa-María; Laura Vallés-Saiz; Félix Hernandez; Jesús Avila

  • Peptide Family Promotes Brain Cell Rejuvenation and Improved Cognition through Peripheral Delivery

    ACS Omega
    2025-04-08 | Journal article
    DOI: 10.1021/acsomega.4c10849
    CONTRIBUTORS: Alejandro Anton-Fernandez; Indalo Domene-Serrano; Raquel Cuadros; Rocio Peinado-Cahuchola; Margarita Sanchez-Pece; Felix Hernandez; Jesus Avila

  • Partial reprogramming by cyclical overexpression of Yamanaka factors improves pathological phenotypes of tauopathy mouse model of human Alzheimer\’s disease

    Progress In Neurobiology
    2025-04-01 | Journal article | Author
    DOI: 10.1016/j.pneurobio.2025.102743

    SOURCE-WORK-ID:

    CSIC-GB950859

    EID:

    2-s2.0-85219079150

    Part ofISSN: 0301-0082
    CONTRIBUTORS: Alejandro Anton-Fernandez; Ruiz de Alegría, Álvaro; Mariscal-Casero, Ana; Roldán-Lázaro, Marta; Peinado-Cauchola, Rocío; Jesus Avila; Felix Hernandez

  • Hippocampal rejuvenation by a single intracerebral injection of one‐carbon metabolites in C57BL6 old wild‐type mice

    Aging Cell
    2025-01 | Journal article
    DOI: 10.1111/acel.14365
    CONTRIBUTORS: Alejandro Antón‐Fernández; Rocío Peinado Cauchola; Félix Hernández; Jesús Ávila

  • Intron retention as a productive mechanism in human MAPT: RNA species generated by retention of intron 3

    eBioMedicine
    2024 | Journal article
    DOI: 10.1016/j.ebiom.2023.104953

    EID:

    2-s2.0-85181837483

    Part ofISSN: 23523964
    CONTRIBUTORS: Ruiz-Gabarre, D.; Vallés-Saiz, L.; Carnero-Espejo, A.; Ferrer, I.; Hernández, F.; Garcia-Escudero, R.; Ávila, J.; García-Escudero, V.

  • Involvement of the cellular prion protein in seeding and spreading of sarkosyl-derived fractions of Alzheimer´s disease in Prnp mutant mice and in the P301S transgenic tauopathy mice model

    bioRxiv
    2024 | Other
    DOI: 10.1101/2024.01.20.576414

    EID:

    2-s2.0-85184321414

    Part of ISSN: 26928205
    CONTRIBUTORS: Sala-Jarque, J.; Gil, V.; Andrés-Benito, P.; Lidón, L.; Yanac-Huertas, R.E.; López-León, C.F.; Hernández, F.; Ávila, J.; Lanciego, J.L.; Soriano, J. et al.

Adithi Randeni | Transcytosis Mechanisms and Hydrocephalus Pathophysiology | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Adithi Randeni | Transcytosis Mechanisms and Hydrocephalus Pathophysiology | Best Researcher Award

Leeds Teaching Hospitals Trust, United Kingdom

Dr. Randeni A. Adithi H. Randeni is a Foundation Year One doctor at Leeds Teaching Hospital Trust with a dynamic portfolio in clinical research, innovation, and academic leadership. A graduate of the University of Leeds (MBChB), she has gained international exposure through observerships and research collaborations in the UK and USA, including SUNY Upstate. Her scholarly contributions span neurosurgery, cerebrospinal fluid dynamics, and biomedical innovation, with publications in top-tier journals such as IJMS, BJS, and BMC Medical Education. Dr. Randeni has received numerous awards and bursaries and is an active educator and mentor. Her leadership roles in university bodies and national societies reflect her commitment to academic excellence and inclusivity. With a future goal of specializing in neurosurgery, she aims to contribute to translational research and advance surgical practice globally through innovation and collaboration.

Profile

🎓 Education

Dr. Adithi Randeni earned her Bachelor of Medicine and Bachelor of Surgery (MBChB) from the University of Leeds, where she excelled in both academic and research endeavors. Her education was enriched by multiple research projects and electives across the UK and internationally, including SUNY Upstate Medical University in the USA. During her time at Leeds, she engaged deeply with translational research, contributing to projects on hydrocephalus, tissue engineering, neurotrauma, and breast cancer genetics. Her academic training included structured research programs and specialized modules in biomedical innovation, CSF dynamics, and advanced surgical techniques. She also undertook audits, systematic reviews, and service evaluations during clinical placements. Beyond formal education, she participated in national research fellowships and student interest groups that fostered interdisciplinary learning and mentorship. Dr. Randeni’s educational journey reflects a strong integration of clinical knowledge with scientific inquiry, preparing her for a future as a research-driven neurosurgeon and academic leader.

🧪 Experience

Dr. Adithi Randeni currently serves as a Foundation Year One doctor at Leeds Teaching Hospital Trust, where she is engaged in hands-on patient care, audits, and quality improvement projects. She has amassed extensive research experience through clinical, translational, and lab-based projects, including those at SUNY Upstate and the University of Leeds. Her past roles include conducting systematic reviews, performing service evaluations in neurosurgery, and leading national student surveys like SMART. She has presented her findings at both national and international conferences and has co-authored peer-reviewed articles and a book chapter. In addition to clinical duties, she has held leadership roles in student organizations, served as a medical student representative, and organized educational workshops. Her involvement with professional societies and interdisciplinary teams highlights her ability to balance clinical work, academic productivity, and collaborative initiatives, making her a well-rounded early-career professional with a clear trajectory in neurosurgical research and innovation.

🏅 Awards and Honors

Dr. Adithi Randeni has been the recipient of numerous academic awards, conference bursaries, and leadership recognitions during her medical training. Her achievements include international presentation opportunities and publication accolades for research on hydrocephalus, surgical outcomes, and student engagement in research pathways. She was invited to co-author a chapter in Springer’s “Arachnoid Cysts: State-of-the-Art” and has contributed to high-impact journals like the British Journal of Surgery and BMC Medical Education. She has earned research travel grants, elective placement scholarships, and teaching recognitions for organizing peer education workshops. Active in student leadership, she received commendations for her roles within the Medical Student Representative Council and societies such as NANSIG and the National MedTech Foundation. Her selection for the “Best Researcher Award” nomination reflects her growing influence in academic medicine. These honors affirm her commitment to excellence in research, innovation, and medical education at an early stage of her professional journey.

🔬 Research Focus

Dr. Adithi Randeni’s research focus lies at the intersection of neurosurgery, cerebrospinal fluid (CSF) dynamics, and biomedical innovation. She has explored pathological mechanisms such as abnormal transcytosis in hydrocephalus, authored a chapter on the genetics of arachnoid cysts, and is actively investigating CSF composition in hydrocephalus through collaborations with SUNY Upstate. Her research interests also include neurotrauma, surgical outcomes, antimicrobial stewardship, and tissue-engineered cardiovascular grafts. With a strong inclination toward translational research, she integrates clinical insights with lab-based findings to drive innovation. Dr. Randeni also explores medical education, having co-led the SMART study on student engagement in research. Her contributions aim to bridge the gap between bedside care and bench science, with ongoing work assessing surgical site infections and diagnostic accuracy in neurosurgical imaging. She is passionate about leveraging biomedical research and digital tools to enhance patient outcomes and surgical practice, particularly in underserved and complex neurological conditions.

✅ Conclusion

Dr. Adithi Randeni exemplifies the fusion of clinical excellence, research innovation, and educational leadership, positioning her as a promising future leader in neurosurgery and translational science.

Publications

  • Abnormal Transcytosis Mechanisms in the Pathogenesis of Hydrocephalus: A Review

    International Journal of Molecular Sciences
    2025-05-19 | Journal article
    DOI: 10.3390/ijms26104881
    Part ofISSN: 1422-0067
    CONTRIBUTORS: Adithi Randeni; Sydney Colvin; Satish Krishnamurthy

  • Genetics of Arachnoid Cysts

    Arachnoid Cysts
    2023 | Book chapter
    DOI: 10.1007/978-3-031-22701-1_8
    Part ofISBN: 9783031227004
    Part ofISBN: 9783031227011
    CONTRIBUTORS: Adithi Randeni; Sydney Colvin; Satish Krishnamurth

  • Cross-sectional Survey of Medical student perceptions of And desires for Research and Training pathways (SMART): an analysis of prospective cohort study of UK medical students

    BMC Medical Education
    2023-12-15 | Journal article
    DOI: 10.1186/s12909-023-04881-2
    Part of ISSN: 1472-6920
    CONTRIBUTORS: Gokul Parameswaran; Amelia Bowman; Catherine Swales; Setthasorn Zhi Yang Ooi; Shie Wei Chan; Priya Rose Babu; Daniele Ramsay; Sofia Kostoudi; Soham Bandyopadhyay; SMART-NANSIG-InCiSion Collaborative et al.

Pin Wang | Neuroimmunology | Best Researcher Award

Published on by Cognitive Scientist Awards

Dr. Pin Wang | Neuroimmunology | Best Researcher Award

Dr. Pin Wang, a female medical doctor and postdoctoral researcher, is an Associate Chief Physician in Neurology at the Second Hospital of Shandong University. She earned her PhD in Neurology from Shandong University in 2009 and was a visiting scholar at the NIH, USA. She specializes in neuroimmunology, focusing on multiple sclerosis and related disorders. Dr. Wang has led research funded by the Shandong Natural Science Foundation and the Department of Education, with multiple SCI-indexed publications.

Profile

Education 🎓

Dr. Wang obtained her PhD in Neurology from Shandong University School of Medicine in 2009. From 2012 to 2013, she trained at the National Institute of Neurological Disorders and Stroke (NINDS), NIH, under Dr. Bibiana Bielekova, focusing on immune-mediated neurological diseases. Her education integrates clinical neurology, research, and teaching, positioning her as an expert in demyelinating diseases and neuroimmune disorders.

Experience 👨‍🏫

Dr. Wang has extensive experience in neurology, combining clinical practice, teaching, and research. She worked at NIH, studying neuroimmune disease mechanisms and participated in the FDA-approved daclizumab clinical trials for multiple sclerosis. She is an Associate Chief Physician at Shandong University’s Second Hospital and actively contributes to patient care, student training, and neurological research, particularly in neuroimmunology.

Research Interests 🔬

Dr. Wang specializes in multiple sclerosis, neuromyelitis optica, myelitis, optic neuritis, acute disseminated encephalomyelitis, and myasthenia gravis. Her research explores immune-mediated neurological diseases, oxidative stress in demyelination, and environmental neurotoxins in neurodegenerative disorders like Alzheimer’s disease.

Dr. Wang has received funding from the Shandong Natural Science Foundation and the Department of Education for her research in neurological disorders. Her contributions to neuroimmunology have been recognized through multiple SCI publications and conference presentations. She plays an active role in professional neurology and immunology committees in Shandong Province.

Publications 📚

Carmela Conte | Neurodegenerative diseases | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof Dr. Carmela Conte | Neurodegenerative diseases | Best Researcher Award

 

Profile

Education

Carmela Conte obtained her Master’s degree in Biological Sciences from the University of Perugia on November 3, 1994. She then pursued a Ph.D. in Medical Embryology through a joint program between the Universities of Perugia and Ferrara, completing it between December 30, 1996, and January 19, 2000. Following this, she specialized in Chemistry and Food Technology at the University of Perugia, earning her specialization between November 1, 2000, and November 1, 2002. Most recently, on September 29, 2023, she received National Habilitation as an Associate Professor in Biochemistry. She currently serves as an Aggregate Professor in her field.

Work experience

Since September 7, 2007, Carmela Conte has been serving as an Aggregate Professor in Biochemistry at the University of Perugia, where she teaches courses in General and Systematic Biochemistry, Medical Applied Biochemistry, and Molecular Biology. In addition to her teaching responsibilities, she participated in a Teaching and Training Mobility Program at VUMC Medical University of Amsterdam from June 24 to July 5, 2019, where she worked on a research project investigating the role of Toll-like receptors in Parkinson’s disease. She has been a member of the European Society for Neurochemistry since 2007 and, since March 17, 2022, has also been affiliated with the International Parkinson and Movement Disorder Society.

Research Activity

Carmela Conte’s research focuses on neurodegenerative diseases, with particular emphasis on animal models, signal transduction, molecular biology, and cell biology. Her specific research topics include the role of Toll-like receptors in Parkinson’s disease, neuroinflammation, synucleinopathies, oxidative stress, and Parkinson’s disease. Since September 7, 2007, she has been actively involved in editorial work, serving as a Reviewer Editor for Frontiers in Neuroscience (Neurodegeneration section) and as an ad hoc reviewer for several journals, including Amino Acids, The Cerebellum, Free Radical Research, Biomolecules, PLOS One, Experimental Gerontology, Molecules, Cells, Neurochemical Research, Neuroscience, Pharmacological Reports, International Journal of Molecular Sciences, Viruses, and the Journal of Biotechnology. Additionally, she has been a Guest Editor for Molecules and Cells, overseeing special issues and topic collections on neurodegenerative diseases. She has presented her research at numerous scientific meetings and conferences, including the 2009 Meeting of the European Society for Neurochemistry in Leipzig, the 2019 European Biotechnology Congress in Valencia, the 2021 European Biotechnology Congress in Sofia, the 2022 National Meeting of the Sphingolipid Club, and the 2023 Meeting of Parkinson’s Disease and Movement Disorders, where she discussed findings related to Toll-like receptor 4, alpha-synuclein accumulation, and sphingomyelinase activity in Parkinson’s disease models.

Publication